MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
Public ClinicalTrials.gov record NCT01792518. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Evaluate linagliptin in terms of glycemic control as defined by HbA1c after 24 weeks of treatment and in terms of renal efficacy as defined by changes in albuminuria (UACR) after 24 weeks of treatment.
Study identification
- NCT ID
- NCT01792518
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 360 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 31, 2013
- Primary completion
- Oct 31, 2015
- Completion
- Nov 30, 2015
- Last update posted
- Mar 5, 2017
2013 – 2015
United States locations
- U.S. sites
- 15
- U.S. states
- 13
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Boehringer Ingelheim Investigational Site | Birmingham | Alabama | — | — |
| Boehringer Ingelheim Investigational Site | Long Beach | California | — | — |
| Boehringer Ingelheim Investigational Site | North Hollywood | California | — | — |
| Boehringer Ingelheim Investigational Site | Denver | Colorado | — | — |
| Boehringer Ingelheim Investigational Site | Miami | Florida | — | — |
| Boehringer Ingelheim Investigational Site | Evansville | Indiana | — | — |
| Boehringer Ingelheim Investigational Site | Flint | Michigan | — | — |
| Boehringer Ingelheim Investigational Site | Jackson | Mississippi | — | — |
| Boehringer Ingelheim Investigational Site | Asheboro | North Carolina | — | — |
| Boehringer Ingelheim Investigational Site | Charlotte | North Carolina | — | — |
| Boehringer Ingelheim Investigational Site | Fargo | North Dakota | — | — |
| Boehringer Ingelheim Investigational Site | Columbus | Ohio | — | — |
| Boehringer Ingelheim Investigational Site | Oklahoma City | Oklahoma | — | — |
| Boehringer Ingelheim Investigational Site | Knoxville | Tennessee | — | — |
| Boehringer Ingelheim Investigational Site | Houston | Texas | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 59 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01792518, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 5, 2017 · Synced Sep 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01792518 live on ClinicalTrials.gov.